The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a problem not yet solved same for all drug-eluting stents. The Absorb (Abbott Vascular, Abbott Park, IL, USA) is the first absorbable vascular support approved for clinical use. The EVERBIO II study was designed to compare the safety and efficacy of the Absorb platform versus everolimus-eluting stent (Promus) and biolimus eluting stent (Biomatrix). 240 patients were randomized to Absorb, Biomatrix, or Promus (80 in each group) and all underwent follow-up angiography at 9 months. In the Absorb group a greater late lumen loss in the segment (not in-stent) compared to the two metal stents was observed. No differences in death, myocardial infarction, or target vessel revascularization were observed. A definitive thrombosis at 263 days after implantation corresponding to a patient who had received Absorb was observed.
Conclusion
In a real-world population, the bio-absorbable Absorb stent showed comparable clinical and angiographic outcomes to everolimus and biolimus eluting stents.
Stéphane Cook
2014-09-17
Original title: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease.
